Search

Your search keyword '"de Vries, I Jolanda M"' showing total 822 results
Start Over Author "de Vries, I Jolanda M"
822 results on '"de Vries, I Jolanda M"'

1. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

Author

Alves Costa Silva, Carolina, Piccinno, Gianmarco, Suissa, Déborah, Bourgin, Mélanie, Schreibelt, Gerty, Durand, Sylvère, Birebent, Roxanne, Fidelle, Marine, Sow, Cissé, Aprahamian, Fanny, Manghi, Paolo, Punčochář, Michal, Asnicar, Francesco, Pinto, Federica, Armanini, Federica, Terrisse, Safae, Routy, Bertrand, Drubay, Damien, Eggermont, Alexander M. M., Kroemer, Guido, Segata, Nicola, Zitvogel, Laurence, Derosa, Lisa, Bol, Kalijn F., and de Vries, I. Jolanda M.

Published
2024
Full Text
View/download PDF

2. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Author

Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J. H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A. M., van Oorschot, Tom G. M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W. M. M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H. A., Wortel, Inge M. N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E. M., Bonenkamp, Johannes J., Haanen, John B. A. G., Boers-Sonderen, Marye J., Koornstra, Rutger H. T., Boomsma, Martijn F., Aarntzen, Erik H. J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J. M., Figdor, Carl G., de Wilt, Johannes H. W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., and de Vries, I. Jolanda M.

Published
2024
Full Text
View/download PDF

6. Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways

Author

van Wigcheren, Glenn F., Cuenca-Escalona, Jorge, Stelloo, Suzan, Brake, Julia, Peeters, Eline, Horrevorts, Sophie.K., Frölich, Siebren, Ramos-Tomillero, Iván, Wesseling-Rozendaal, Yvonne, van Herpen, Carla M.L., van de Stolpe, Anja, Vermeulen, Michiel, de Vries, I. Jolanda M., Figdor, Carl G., and Flórez-Grau, Georgina

Published
2023
Full Text
View/download PDF

8. Fully closed and automated enrichment of primary blood dendritic cells for cancer immunotherapy

Author

Schreibelt, Gerty, primary, Duiveman-de Boer, Tjitske, additional, Pots, Jeanette M., additional, van Oorschot, Tom G.M., additional, de Boer, Annemiek J., additional, Scharenborg, Nicole M., additional, van de Rakt, Mandy W.M.M., additional, Bos, Kevin, additional, de Goede, Anna L., additional, Petry, Katja, additional, Brüning, Mareke, additional, Angerer, Caroline, additional, Schöggl, Carola, additional, Dzionek, Andreas, additional, and de Vries, I. Jolanda M., additional

Published
2023
Full Text
View/download PDF

9. Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer.

Author

Bakkerus, Lotte, Subtil, Beatriz, Bontkes, Hetty J., Gootjes, Elske C., Reijm, Martine, Vullings, Manon, Verrijp, Kiek, Bokhorst, John-Melle, Woortman, Carmen, Nagtegaal, Iris D., Jonker, Marianne A., van der Vliet, Hans J., Verhoef, Cornelis, Gorris, Mark A.J., de Vries, I. Jolanda M., de Gruijl, Tanja D., Verheul, Henk M.W., Buffart, Tineke E., and Tauriello, Daniele V. F.

Abstract

Colorectal cancer (CRC) raises considerable clinical challenges, including a high mortality rate once the tumor spreads to distant sites. At this advanced stage, more accurate prediction of prognosis and treatment outcome is urgently needed. The role of cancer immunity in metastatic CRC (mCRC) is poorly understood. Here, we explore cellular immune cell status in patients with multi-organ mCRC. We analyzed T cell infiltration in primary tumor sections, surveyed the lymphocytic landscape of liver metastases, and assessed circulating mononuclear immune cells. Besides asking whether immune cells are associated with survival at this stage of the disease, we investigated correlations between the different tissue types; as this could indicate a dominant immune phenotype. Taken together, our analyses corroborate previous observations that higher levels of CD8+ T lymphocytes link to better survival outcomes. Our findings therefore extend evidence from earlier stages of CRC to indicate an important role for cancer immunity in disease control even after metastatic spreading to multiple organs. This finding may help to improve predicting outcome of patients with mCRC and suggests a future role for immunotherapeutic strategies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

Author

MS Hematologie, Alves Costa Silva, Carolina, Piccinno, Gianmarco, Suissa, Déborah, Bourgin, Mélanie, Schreibelt, Gerty, Durand, Sylvère, Birebent, Roxanne, Fidelle, Marine, Sow, Cissé, Aprahamian, Fanny, Manghi, Paolo, Punčochář, Michal, Asnicar, Francesco, Pinto, Federica, Armanini, Federica, Terrisse, Safae, Routy, Bertrand, Drubay, Damien, Eggermont, Alexander M.M., Kroemer, Guido, Segata, Nicola, Zitvogel, Laurence, Derosa, Lisa, Bol, Kalijn F., de Vries, I. Jolanda M., MS Hematologie, Alves Costa Silva, Carolina, Piccinno, Gianmarco, Suissa, Déborah, Bourgin, Mélanie, Schreibelt, Gerty, Durand, Sylvère, Birebent, Roxanne, Fidelle, Marine, Sow, Cissé, Aprahamian, Fanny, Manghi, Paolo, Punčochář, Michal, Asnicar, Francesco, Pinto, Federica, Armanini, Federica, Terrisse, Safae, Routy, Bertrand, Drubay, Damien, Eggermont, Alexander M.M., Kroemer, Guido, Segata, Nicola, Zitvogel, Laurence, Derosa, Lisa, Bol, Kalijn F., and de Vries, I. Jolanda M.

Published
2024

12. cDC2 plasticity and acquisition of a DC3-like phenotype mediated by IL-6 and PGE2 in a patient-derived colorectal cancer organoids model

Author

Subtil, Beatriz, van der Hoorn, Iris A. E., Cuenca-Escalona, Jorge, Becker, Anouk M. D., Alvarez-Begue, Mar, Iyer, Kirti K., Janssen, Jorien, van Oorschot, Tom, Poel, Dennis, Gorris, Mark A. J., van den Dries, Koen, Cambi, Alessandra, Tauriello, Daniele V. F., de Vries, I. Jolanda M., Subtil, Beatriz, van der Hoorn, Iris A. E., Cuenca-Escalona, Jorge, Becker, Anouk M. D., Alvarez-Begue, Mar, Iyer, Kirti K., Janssen, Jorien, van Oorschot, Tom, Poel, Dennis, Gorris, Mark A. J., van den Dries, Koen, Cambi, Alessandra, Tauriello, Daniele V. F., and de Vries, I. Jolanda M.

Abstract

Metastatic colorectal cancer (CRC) is highly resistant to therapy and prone to recur. The tumor-induced local and systemic immunosuppression allows cancer cells to evade immunosurveillance, facilitating their proliferation and dissemination. Dendritic cells (DCs) are required for the detection, processing, and presentation of tumor antigens, and subsequently for the activation of antigen-specific T cells to orchestrate an effective antitumor response. Notably, successful tumors have evolved mechanisms to disrupt and impair DC functions, underlining the key role of tumor-induced DC dysfunction in promoting tumor growth, metastasis initiation, and treatment resistance. Conventional DC type 2 (cDC2) are highly prevalent in tumors and have been shown to present high phenotypic and functional plasticity in response to tumor-released environmental cues. This plasticity reverberates on both the development of antitumor responses and on the efficacy of immunotherapies in cancer patients. Uncovering the processes, mechanisms, and mediators by which CRC shapes and disrupts cDC2 functions is crucial to restoring their full antitumor potential. In this study, we use our recently developed 3D DC-tumor co-culture system to investigate how patient-derived primary and metastatic CRC organoids modulate cDC2 phenotype and function. We first demonstrate that our collagen-based system displays extensive interaction between cDC2 and tumor organoids. Interestingly, we show that tumor-corrupted cDC2 shift toward a CD14+ population with defective expression of maturation markers, an intermediate phenotype positioned between cDC2 and monocytes, and impaired T-cell activating abilities. This phenotype aligns with the newly defined DC3 (CD14(+) CD1c(+) CD163(+)) subset. Remarkably, a comparable population was found to be present in tumor lesions and enriched in the peripheral blood of metastatic CRC patients. Moreover, using EP2 and EP4 receptor antagonists and an anti-IL-6 neutralizing antib

Published
2024

13. Design of TOLERANT: phase I/II safety assessment of intranodal administration of HSP70/mB29a self-peptide antigen-loaded autologous tolerogenic dendritic cells in patients with rheumatoid arthritis

Author

Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodology, Apotheek Celtherapie Faciliteit, Apotheek Veiligheid en Kwaliteit, Stoppelenburg, Arie Jan, Schreibelt, Gerty, Koeneman, Bouke, Welsing, Paco, Breman, Evert-Jan, Lammers, Laureen, de Goede, Anna, Duiveman-de Boer, Tjitske, van Eden, Willem, Leufkens, Paul, de Vries, I Jolanda M, Broere, Femke, van Laar, Jacob M, Lab Reumatologie/Klinische Immunologie, Infection & Immunity, MS Reumatologie/Immunologie/Infectie, Regenerative Medicine and Stem Cells, JC onderzoeksprogramma Methodology, Apotheek Celtherapie Faciliteit, Apotheek Veiligheid en Kwaliteit, Stoppelenburg, Arie Jan, Schreibelt, Gerty, Koeneman, Bouke, Welsing, Paco, Breman, Evert-Jan, Lammers, Laureen, de Goede, Anna, Duiveman-de Boer, Tjitske, van Eden, Willem, Leufkens, Paul, de Vries, I Jolanda M, Broere, Femke, and van Laar, Jacob M

Published
2024

14. Adjuvant dendritic cell therapy in stage IIIB/C melanoma:the MIND-DC randomized phase III trial

Author

Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J.H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A.M., van Oorschot, Tom G.M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W.M.M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H.A., Wortel, Inge M.N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E.M., Bonenkamp, Johannes J., Haanen, John B.A.G., Boers-Sonderen, Marye J., Koornstra, Rutger H.T., Boomsma, Martijn F., Aarntzen, Erik H.J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J.M., Figdor, Carl G., de Wilt, Johannes H.W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., de Vries, I. Jolanda M., Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J.H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A.M., van Oorschot, Tom G.M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W.M.M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., Koeneman, Bouke J., Creemers, Jeroen H.A., Wortel, Inge M.N., Angerer, Caroline, Brüning, Mareke, Petry, Katja, Dzionek, Andrzej, van der Veldt, Astrid A., van Grünhagen, Dirk J., Werner, Johanna E.M., Bonenkamp, Johannes J., Haanen, John B.A.G., Boers-Sonderen, Marye J., Koornstra, Rutger H.T., Boomsma, Martijn F., Aarntzen, Erik H.J., Gotthardt, Martin, Nagarajah, James, de Witte, Theo J.M., Figdor, Carl G., de Wilt, Johannes H.W., Textor, Johannes, de Groot, Jan Willem B., Gerritsen, Winald R., and de Vries, I. Jolanda M.

Abstract

Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88−1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73−2.38; p = 0.44). Grade 3−4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed.

Published
2024

15. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings

Author

ten Ham, Renske M.T., Hövels, Anke M., Hoekman, Jarno, Frederix, Geert W.J., Leufkens, Hubert G.M., Klungel, Olaf H., Jedema, Inge, Veld, Sabrina A.J., Nikolic, Tatjana, Van Pel, Melissa, Zwaginga, Jaap J., Lin, Fong, de Goede, Anna L., Schreibelt, Gerty, Budde, Sandy, de Vries, I. Jolanda M., Wilkie, Gwen M., Dolstra, Harry, Ovelgönne, Hans, Meij, Pauline, Mountford, Joanne C., Turner, Marc L., and Hoefnagel, Marcel H.N.

Published
2020
Full Text
View/download PDF

20. Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

Author

Boudewijns, Steve, Bloemendal, Martine, de Haas, Nienke, Westdorp, Harm, Bol, Kalijn F., Schreibelt, Gerty, Aarntzen, Erik H. J. G., Lesterhuis, W. Joost, Gorris, Mark A. J., Croockewit, Alexandra, van der Woude, Lieke L., van Rossum, Michelle M., Welzen, Marieke, de Goede, Anna, Hato, Stanleyson V., van der Graaf, Winette T. A., Punt, Cornelis J. A., Koornstra, Rutger H. T., Gerritsen, Winald R., Figdor, Carl G., and de Vries, I. Jolanda M.

Published
2020
Full Text
View/download PDF

22. Detection of Dendritic Cell Subsets in the Tumor Microenvironment by Multiplex Immunohistochemistry

Author

van der Hoorn, Iris A.E., primary, Martynova, Evgenia, additional, Subtil, Beatriz, additional, Meek, Jelena, additional, Verrijp, Kiek, additional, Textor, Johannes, additional, Flórez‐Grau, Georgina, additional, Piet, Berber, additional, van den Heuvel, Michel M., additional, de Vries, I. Jolanda M., additional, and Gorris, Mark A. J., additional

Published
2023
Full Text
View/download PDF

24. In vivo imaging of therapy-induced anti-cancer immune responses in humans

Author

Aarntzen, Erik HJG, Srinivas, Mangala, Radu, Caius G, Punt, Cornelis JA, Boerman, Otto C, Figdor, Carl G, Oyen, Wim JG, and de Vries, I Jolanda M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Biomedical Imaging, Vaccine Related, Cancer, Cancer Vaccines, Diagnostic Imaging, Humans, Immunity, Active, Immunotherapy, Lymph Nodes, Lymphocyte Activation, Models, Immunological, Neoplasms, Functional imaging, Dendritic cells, PET, Scintigraphy, MRI, Biochemistry and Cell Biology, Physiology, Clinical Sciences, Biochemistry & Molecular Biology, Biochemistry and cell biology, Medical biochemistry and metabolomics, Oncology and carcinogenesis
Abstract

Immunotherapy aims to re-engage and revitalize the immune system in the fight against cancer. Research over the past decades has shown that the relationship between the immune system and human cancer is complex, highly dynamic, and variable between individuals. Considering the complexity, enormous effort and costs involved in optimizing immunotherapeutic approaches, clinically applicable tools to monitor therapy-induced immune responses in vivo are most warranted. However, the development of such tools is complicated by the fact that a developing immune response encompasses several body compartments, e.g., peripheral tissues, lymph nodes, lymphatic and vascular systems, as well as the tumor site itself. Moreover, the cells that comprise the immune system are not static but constantly circulate through the vascular and lymphatic system. Molecular imaging is considered the favorite candidate to fulfill this task. The progress in imaging technologies and modalities has provided a versatile toolbox to address these issues. This review focuses on the detection of therapy-induced anticancer immune responses in vivo and provides a comprehensive overview of clinically available imaging techniques as well as perspectives on future developments. In the discussion, we will focus on issues that specifically relate to imaging of the immune system and we will discuss the strengths and limitations of the current clinical imaging techniques. The last section provides future directions that we envision to be crucial for further development.

Published
2013

26. Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment

Author

Gorris, Mark A. J., primary, Martynova, Evgenia, additional, Sweep, Mark W. D., additional, van der Hoorn, Iris A. E., additional, Sultan, Shabaz, additional, Claassens, Mike J. D. E., additional, van der Woude, Lieke L., additional, Verrijp, Kiek, additional, Figdor, Carl G., additional, Textor, Johannes, additional, and de Vries, I. Jolanda M., additional

Published
2023
Full Text
View/download PDF

29. Detection of dendritic cell subsets in the tumor microenvironment by multiplex immunohistochemistry.

Author

van der Hoorn, Iris A.E., Martynova, Evgenia, Subtil, Beatriz, Meek, Jelena, Verrijp, Kiek, Textor, Johannes, Flórez‐Grau, Georgina, Piet, Berber, van den Heuvel, Michel M., de Vries, I. Jolanda M., and Gorris, Mark A. J.

Subjects
TUMOR microenvironment, DENDRITIC cells, IMMUNOHISTOCHEMISTRY, CELL suspensions
Abstract

Dendritic cells (DCs) are essential in antitumor immunity. In humans, three main DC subsets are defined: two types of conventional DCs (cDC1s and cDC2s) and plasmacytoid DCs (pDCs). To study DC subsets in the tumor microenvironment (TME), it is important to correctly identify them in tumor tissues. Tumor‐derived DCs are often analyzed in cell suspensions in which spatial information about DCs which can be important to determine their function within the TME is lost. Therefore, we developed the first standardized and optimized multiplex immunohistochemistry panel, simultaneously detecting cDC1s, cDC2s, and pDCs within their tissue context. We report on this panel's development, validation, and quantitative analysis. A multiplex immunohistochemistry panel consisting of CD1c, CD303, X‐C motif chemokine receptor 1, CD14, CD19, a tumor marker, and DAPI was established. The ImmuNet machine learning pipeline was trained for the detection of DC subsets. The performance of ImmuNet was compared with conventional cell phenotyping software. Ultimately, frequencies of DC subsets within several tumors were defined. In conclusion, this panel provides a method to study cDC1s, cDC2s, and pDCs in the spatial context of the TME, which supports unraveling their specific roles in antitumor immunity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Microbiota-associated metabolic reprograming influenced clinical outcome in the randomized dendritic cell-based clinical trial in stage III melanoma

Author

ALVES-COSTA-SILVA, Carolina, primary, Bourgin, Mélanie, additional, Piccinno, Gianmarco, additional, Schreibelt, Gerty, additional, Durand, Sylvère, additional, Fidelle, Marine, additional, Sow, Cissé, additional, Birebent, Roxanne, additional, Aprahamian, Fanny, additional, Manghi, Paolo, additional, Asnicar, Francesco, additional, Pinto, Federica, additional, Armanini, Federica, additional, Terrisse, Safae, additional, Routy, Bertrand, additional, Eggermont, Alexander, additional, Kroemer, Guido, additional, Segata, Nicola, additional, Derosa, Lisa, additional, Bol, Kalijn, additional, De Vries, I. Jolanda M., additional, and Zitvogel, Laurence, additional

Published
2023
Full Text
View/download PDF

34. Dendritic cell phenotype and function in a 3D co-culture model of patient-derived metastatic colorectal cancer organoids

Author

Subtil, Beatriz, Iyer, Kirti K. K., Poel, Dennis, Bakkerus, Lotte, Gorris, Mark A. J., Escalona, Jorge Cuenca, Dries, Koen van den, Cambi, Alessandra, Verheul, Henk M. W., de Vries, I. Jolanda M., Tauriello, Daniele V. F., Subtil, Beatriz, Iyer, Kirti K. K., Poel, Dennis, Bakkerus, Lotte, Gorris, Mark A. J., Escalona, Jorge Cuenca, Dries, Koen van den, Cambi, Alessandra, Verheul, Henk M. W., de Vries, I. Jolanda M., and Tauriello, Daniele V. F.

Abstract

Colorectal cancer (CRC) remains one of the most aggressive and lethal cancers, with metastasis accounting for most deaths. As such, there is an unmet need for improved therapies for metastatic CRC (mCRC). Currently, the research focus is shifting towards the reciprocal interactions within the tumor microenvironment (TME), which prevent tumor clearance by the immune system. Dendritic cells (DCs) play a key role in the initiation and amplification of anti-tumor immune responses and in driving the clinical success of immunotherapies. Dissecting the interactions between DCs and CRC cells may open doors to identifying key mediators in tumor progression, and possible therapeutic targets. This requires representative, robust and versatile models and tools. Currently, there is a shortage of such in vitro systems to model the CRC TME and its tumor-immune cell interactions. Here we develop and establish a dynamic organotypic 3D co-culture system to recapitulate and untangle the interactions between DCs and patient-derived mCRC tumor organoids. To our knowledge, this is the first study investigating human DCs in co-culture with tumor organoids in a 3D, organotypic setting. This system reveals how mCRC organoids modulate and shape monocyte-derived DCs (MoDCs) behavior, phenotype, and function, within a collagen matrix, using techniques such as brightfield and fluorescence microscopy, flow cytometry, and fluorescence-activated cell sorting. Our 3D co-culture model shows high viability and extensive interaction between DCs and tumor organoids, and its structure resembles patient tissue sections. Furthermore, it is possible to retrieve DCs from the co-cultures and characterize their phenotypic and functional profile. In our study, the expression of activation markers in both mature and immature DCs and their ability to activate T cells were impacted by co-culture with tumor organoids. In the future, this direct co-culture platform can be adapted and exploited to study the CRC-D

Published
2023

35. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Author

Westdorp, Harm, Creemers, Jeroen H. A., van Oort, Inge M., Schreibelt, Gerty, Gorris, Mark A. J., Mehra, Niven, Simons, Michiel, de Goede, Anna L., van Rossum, Michelle M., Croockewit, Alexandra J., Figdor, Carl G., Witjes, J. Alfred, Aarntzen, Erik H. J. G., Mus, Roel D. M., Brüning, Mareke, Petry, Katja, Gotthardt, Martin, Barentsz, Jelle O., de Vries, I. Jolanda M., and Gerritsen, Winald R.

Published
2019
Full Text
View/download PDF

37. Supplementary Table 1 from T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

Author

Vasaturo, Angela, primary, Halilovic, Altuna, primary, Bol, Kalijn F., primary, Verweij, Dagmar I., primary, Blokx, Willeke A.M., primary, Punt, Cornelis J.A., primary, Groenen, Patricia J.T.A., primary, van Krieken, J. Han J.M., primary, Textor, Johannes, primary, de Vries, I. Jolanda M., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure legend from T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

Author

Vasaturo, Angela, primary, Halilovic, Altuna, primary, Bol, Kalijn F., primary, Verweij, Dagmar I., primary, Blokx, Willeke A.M., primary, Punt, Cornelis J.A., primary, Groenen, Patricia J.T.A., primary, van Krieken, J. Han J.M., primary, Textor, Johannes, primary, de Vries, I. Jolanda M., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Table 1 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 2 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 1 from T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

Author

Vasaturo, Angela, primary, Halilovic, Altuna, primary, Bol, Kalijn F., primary, Verweij, Dagmar I., primary, Blokx, Willeke A.M., primary, Punt, Cornelis J.A., primary, Groenen, Patricia J.T.A., primary, van Krieken, J. Han J.M., primary, Textor, Johannes, primary, de Vries, I. Jolanda M., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Data from Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

Author

de Vries, I. Jolanda M., primary, Castelli, Chiara, primary, Huygens, Caroline, primary, Jacobs, Joannes F.M., primary, Stockis, Julie, primary, Schuler-Thurner, Beatrice, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, Rivoltini, Licia, primary, Schuler, Gerold, primary, Coulie, Pierre G., primary, and Lucas, Sophie, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Figure 3 from Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

Author

Aarntzen, Erik H. J. G., primary, Schreibelt, Gerty, primary, Bol, Kalijn, primary, Lesterhuis, W. Joost, primary, Croockewit, Alexandra J., primary, de Wilt, Johannes H. W., primary, van Rossum, Michelle M., primary, Blokx, Willeke A. M., primary, Jacobs, Joannes F. M., primary, Duiveman-de Boer, Tjitske, primary, Schuurhuis, Danita H., primary, Mus, Roel, primary, Thielemans, Kris, primary, de Vries, I. Jolanda M., primary, Figdor, Carl G., primary, Punt, Cornelis J. A., primary, and Adema, Gosse J., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 2 from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Author

Schreibelt, Gerty, primary, Bol, Kalijn F., primary, Westdorp, Harm, primary, Wimmers, Florian, primary, Aarntzen, Erik H.J.G., primary, Duiveman-de Boer, Tjitske, primary, van de Rakt, Mandy W.M.M., primary, Scharenborg, Nicole M., primary, de Boer, Annemiek J., primary, Pots, Jeanette M., primary, Olde Nordkamp, Michel A.M., primary, van Oorschot, Tom G.M., primary, Tel, Jurjen, primary, Winkels, Gregor, primary, Petry, Katja, primary, Blokx, Willeke A.M., primary, van Rossum, Michelle M., primary, Welzen, Marieke E.B., primary, Mus, Roel D.M., primary, Croockewit, Sandra A.J., primary, Koornstra, Rutger H.T., primary, Jacobs, Joannes F.M., primary, Kelderman, Sander, primary, Blank, Christian U., primary, Gerritsen, Winald R., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure 3 from Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

Author

Schreibelt, Gerty, primary, Bol, Kalijn F., primary, Westdorp, Harm, primary, Wimmers, Florian, primary, Aarntzen, Erik H.J.G., primary, Duiveman-de Boer, Tjitske, primary, van de Rakt, Mandy W.M.M., primary, Scharenborg, Nicole M., primary, de Boer, Annemiek J., primary, Pots, Jeanette M., primary, Olde Nordkamp, Michel A.M., primary, van Oorschot, Tom G.M., primary, Tel, Jurjen, primary, Winkels, Gregor, primary, Petry, Katja, primary, Blokx, Willeke A.M., primary, van Rossum, Michelle M., primary, Welzen, Marieke E.B., primary, Mus, Roel D.M., primary, Croockewit, Sandra A.J., primary, Koornstra, Rutger H.T., primary, Jacobs, Joannes F.M., primary, Kelderman, Sander, primary, Blank, Christian U., primary, Gerritsen, Winald R., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 2 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

47. Data from Cancer Patients Treated with Sunitinib or Sorafenib Have Sufficient Antibody and Cellular Immune Responses to Warrant Influenza Vaccination

Author

Mulder, Sasja F., primary, Jacobs, Joannes F.M., primary, Olde Nordkamp, Michel A.M., primary, Galama, Joep M.D., primary, Desar, Ingrid M.E., primary, Torensma, Ruurd, primary, Teerenstra, Steven, primary, Mulders, Peter F.A., primary, Vissers, Kris C.P., primary, Punt, Cornelis J.A., primary, de Vries, I. Jolanda M., primary, and van Herpen, Carla M.L., primary

Published
2023
Full Text
View/download PDF

48. Supplementary Table 1 from Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells

Author

Aarntzen, Erik H.J.G., primary, Srinivas, Mangala, primary, Bonetto, Fernando, primary, Cruz, Luis J., primary, Verdijk, Pauline, primary, Schreibelt, Gerty, primary, van de Rakt, Mandy, primary, Lesterhuis, W. Joost, primary, van Riel, Maichel, primary, Punt, Cornelius J.A., primary, Adema, Gosse J., primary, Heerschap, Arend, primary, Figdor, Carl G., primary, Oyen, Wim J., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

Author

Lesterhuis, W. Joost, primary, de Vries, I. Jolanda M., primary, Schreibelt, Gerty, primary, Lambeck, Annechien J.A., primary, Aarntzen, Erik H.J.G., primary, Jacobs, Joannes F.M., primary, Scharenborg, Nicole M., primary, van de Rakt, Mandy W.M.M., primary, de Boer, Annemiek J., primary, Croockewit, Sandra, primary, van Rossum, Michelle M., primary, Mus, Roel, primary, Oyen, Wim J.G., primary, Boerman, Otto C., primary, Lucas, Sophie, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

50. Data from T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines

Author

Vasaturo, Angela, primary, Halilovic, Altuna, primary, Bol, Kalijn F., primary, Verweij, Dagmar I., primary, Blokx, Willeke A.M., primary, Punt, Cornelis J.A., primary, Groenen, Patricia J.T.A., primary, van Krieken, J. Han J.M., primary, Textor, Johannes, primary, de Vries, I. Jolanda M., primary, and Figdor, Carl G., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results